Alisha Badal is addressing the challenges of treating aggressive triple-negative breast cancers (TNBC) with BRCA mutations by proposing a strategy that involves molecular gene editing to upregulate a downregulated long-noncoding RNA (lncRNA) gene. This innovative approach aims to restore aberrant regulatory networks in TNBC, testing the synergistic efficacy of a metallotherapy apoptosis agent and a DNA repair inhibitor, offering potential new treatment options for this challenging form of breast cancer.

Further Activities to have a look at